IL150710A0 - Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation - Google Patents

Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Info

Publication number
IL150710A0
IL150710A0 IL15071001A IL15071001A IL150710A0 IL 150710 A0 IL150710 A0 IL 150710A0 IL 15071001 A IL15071001 A IL 15071001A IL 15071001 A IL15071001 A IL 15071001A IL 150710 A0 IL150710 A0 IL 150710A0
Authority
IL
Israel
Prior art keywords
receptor antagonist
smoking cessation
cannabinoid receptor
preparing medicines
central cannabinoid
Prior art date
Application number
IL15071001A
Other languages
English (en)
Original Assignee
Sanofi Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo filed Critical Sanofi Synthelabo
Publication of IL150710A0 publication Critical patent/IL150710A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15071001A 2000-02-09 2001-02-07 Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation IL150710A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0001682A FR2804604B1 (fr) 2000-02-09 2000-02-09 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
PCT/FR2001/000356 WO2001058450A2 (fr) 2000-02-09 2001-02-07 Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Publications (1)

Publication Number Publication Date
IL150710A0 true IL150710A0 (en) 2003-02-12

Family

ID=8846875

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15071001A IL150710A0 (en) 2000-02-09 2001-02-07 Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation

Country Status (33)

Country Link
US (2) US6930122B2 (no)
EP (1) EP1257275B1 (no)
JP (2) JP2003522145A (no)
CN (1) CN1250220C (no)
AR (1) AR028505A1 (no)
AT (1) ATE292467T1 (no)
AU (1) AU781827B2 (no)
BG (2) BG110386A (no)
BR (1) BR0108126A (no)
CA (1) CA2397262C (no)
CZ (1) CZ296685B6 (no)
DE (1) DE60109903T2 (no)
DK (1) DK1257275T3 (no)
EE (1) EE04836B1 (no)
ES (1) ES2240416T3 (no)
FR (1) FR2804604B1 (no)
HK (1) HK1051140A1 (no)
HU (1) HU225328B1 (no)
IL (1) IL150710A0 (no)
IS (1) IS6450A (no)
MX (1) MXPA02007766A (no)
NO (1) NO324521B1 (no)
NZ (1) NZ519924A (no)
PL (1) PL201685B1 (no)
PT (1) PT1257275E (no)
RS (1) RS50404B (no)
RU (1) RU2257207C2 (no)
SI (1) SI1257275T1 (no)
SK (1) SK284952B6 (no)
TW (1) TWI243677B (no)
UA (1) UA72783C2 (no)
WO (1) WO2001058450A2 (no)
ZA (1) ZA200205317B (no)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac
US6462237B1 (en) * 2001-06-14 2002-10-08 Usv Limited Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
EP1417501B1 (en) 2001-08-13 2017-05-31 Finisar Corporation Systems for wafer level burn-in of electronic devices
CA2478183C (en) 2002-03-12 2010-02-16 Merck & Co. Inc. Substituted amides
US7423067B2 (en) 2002-03-26 2008-09-09 Merck & Co., Inc. Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists
CA2479744A1 (en) 2002-03-28 2003-10-09 Paul E. Finke Substituted 2,3-diphenyl pyridines
EP1499306A4 (en) 2002-04-12 2007-03-28 Merck & Co Inc BICYCLIC AMIDE
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
JP4667867B2 (ja) 2002-08-02 2011-04-13 メルク・シャープ・エンド・ドーム・コーポレイション 置換フロ［２，３−ｂ］ピリジン誘導体
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme SUBSTITUTED PYRIMIDINES
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
CN1747926A (zh) 2002-12-19 2006-03-15 麦克公司 取代酰胺化合物
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
US20040224963A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US20040224962A1 (en) * 2003-05-09 2004-11-11 Pfizer Inc Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss
EP1633733B1 (en) * 2003-05-20 2011-01-26 The University of Tennessee Research Foundation Cannabinoid derivatives, methods of making, and use thereof
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
AU2004287849A1 (en) * 2003-10-30 2005-05-19 Merck Sharp & Dohme Corp. Aralkyl amines as cannabinoid receptor modulators
AP2228A (en) 2004-07-12 2011-04-01 Cadila Healthcare Ltd Tricyclic pyrazole derivatives as cannabinoid receptor modulators.
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
MX2007006695A (es) 2004-12-03 2007-08-14 Schering Corp Piperazinas sustituidas como antagonistas de cb1.
MX2008009354A (es) * 2006-01-18 2008-09-30 Schering Corp Moduladores de receptores cannabinoides.
CN101062919B (zh) * 2006-04-26 2012-08-15 中国人民解放军军事医学科学院毒物药物研究所 4-甲基-1h-二芳基吡唑衍生物及其作为药物的用途
WO2007121687A1 (fr) * 2006-04-26 2007-11-01 Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China Dérivés du 4-méthyl-1h-diaryl pyrazole et leur utilisation comme médicaments
US20070287734A1 (en) * 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2477634C2 (ru) * 2006-06-16 2013-03-20 Теракос, Инк. Лечение психологических состояний с применением антагонистов m1-мускариновых рецепторов
EA026213B1 (ru) * 2006-10-20 2017-03-31 Солвей Фармасьютикалс Б.В. Термостабильная твердая фармацевтическая композиция, содержащая наномицеллы, и способ ее получения
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
US20100286160A1 (en) * 2007-06-28 2010-11-11 Intervet Inc. Substituted piperazines as cb1 antagonists
US8623873B2 (en) * 2007-06-28 2014-01-07 Intervet Inc. Substituted piperazines as CB1 antagonists
EP2095814A1 (de) * 2008-02-26 2009-09-02 Wolfgang J. Kox Medikamentengestützter Nikotinentzug
JPWO2010018856A1 (ja) * 2008-08-13 2012-01-26 持田製薬株式会社 カンナビノイド受容体関連疾患の予防／改善または治療剤
RU2533224C2 (ru) * 2010-07-21 2014-11-20 Мапикс Эс.Эй.Ар.Эл. Способ лечения зависимости от психоактивных веществ, алкоголизма и табакокурения и лекарственное средство для лечения зависимости от психоактивных веществ, алкоголизма и табакокурения
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists
WO2014181357A1 (en) * 2013-05-09 2014-11-13 Council Of Scientific & Industrial Research Novel pyrazole derivatives with silicon incorporation
US20200035118A1 (en) 2018-07-27 2020-01-30 Joseph Pandolfino Methods and products to facilitate smokers switching to a tobacco heating product or e-cigarettes
US10897925B2 (en) 2018-07-27 2021-01-26 Joseph Pandolfino Articles and formulations for smoking products and vaporizers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
FR2758723B1 (fr) * 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
FR2765107B1 (fr) * 1997-06-26 2000-03-24 Sanofi Sa Utilisation d'un antagoniste specifique des recepteurs 5ht2 pour la preparation de medicaments utiles dans le traitement du syndrome d'apnee du sommeil
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2804604B1 (fr) * 2000-02-09 2005-05-27 Sanofi Synthelabo Utilisation d'un antagoniste des recepteurs aux cannabinoides centraux pour la preparation de medicaments utiles pour faciliter l'arret de la consommation de tabac

Also Published As

Publication number Publication date
US20030087933A1 (en) 2003-05-08
PL358221A1 (en) 2004-08-09
US6930122B2 (en) 2005-08-16
HUP0300237A3 (en) 2003-09-29
ES2240416T3 (es) 2005-10-16
JP2003522145A (ja) 2003-07-22
AU781827B2 (en) 2005-06-16
PT1257275E (pt) 2005-07-29
CN1406128A (zh) 2003-03-26
RU2002118309A (ru) 2004-02-20
HUP0300237A2 (hu) 2003-07-28
ZA200205317B (en) 2003-09-04
TWI243677B (en) 2005-11-21
FR2804604B1 (fr) 2005-05-27
MXPA02007766A (es) 2002-10-11
FR2804604A1 (fr) 2001-08-10
CA2397262A1 (en) 2001-08-16
BG110386A (en) 2009-09-30
CN1250220C (zh) 2006-04-12
EP1257275B1 (fr) 2005-04-06
NO20023765D0 (no) 2002-08-08
DE60109903T2 (de) 2006-02-09
US20050187253A1 (en) 2005-08-25
SK284952B6 (sk) 2006-03-02
ATE292467T1 (de) 2005-04-15
HK1051140A1 (en) 2003-07-25
CZ296685B6 (cs) 2006-05-17
AU3562001A (en) 2001-08-20
IS6450A (is) 2002-06-28
BR0108126A (pt) 2003-01-28
EE200200439A (et) 2003-12-15
WO2001058450A3 (fr) 2002-04-25
PL201685B1 (pl) 2009-04-30
EE04836B1 (et) 2007-06-15
BG106946A (bg) 2003-05-30
JP2010018622A (ja) 2010-01-28
HU225328B1 (en) 2006-09-28
CA2397262C (en) 2007-09-11
SI1257275T1 (en) 2005-10-31
BG65856B1 (bg) 2010-03-31
SK11292002A3 (sk) 2003-02-04
CZ20022698A3 (cs) 2002-11-13
NO324521B1 (no) 2007-11-12
DE60109903D1 (de) 2005-05-12
RS50404B (sr) 2009-12-31
DK1257275T3 (da) 2005-08-08
RU2257207C2 (ru) 2005-07-27
WO2001058450A2 (fr) 2001-08-16
YU59002A (sh) 2005-07-19
UA72783C2 (en) 2005-04-15
EP1257275A2 (fr) 2002-11-20
NO20023765L (no) 2002-10-09
NZ519924A (en) 2005-01-28
AR028505A1 (es) 2003-05-14

Similar Documents

Publication Publication Date Title
IL150710A0 (en) Use of a central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation
AU7667300A (en) Use of central cannabinoid receptor antagonist for preparing medicines
PL365377A1 (en) Amide derivatives as nmda receptor antagonists
HUP0301671A3 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists, process for their preparation and their use
MXPA03000923A (es) Compuestos de carboxamida y su uso como antagonistas de un receptor 11cby humano.
HUP0302044A3 (en) Association of the cb1 receptor antagonist and a sibutramin, pharmaceutical compositions containing same and use thereof for treating obesity
AU2001235691A1 (en) Use of paullone derivatives for making medicines
HUP0302167A3 (en) Quinoline derivatives as metabotropic glutamate receptor antagonists, pharmaceutical compositions containing them and process for producing them
IL148593A0 (en) T2r, a novel family of taste receptors
PT1347760E (pt) Composicoes farmaceuticas de agonista do receptor de nmda
HUP0700039A2 (en) Use of cannabinoid drugs for the preparation of medicines for decreasing cell proliferation
HUP0302382A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HRP20030031A2 (en) 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists
PL358584A1 (en) Cyclohexylamine derivative as subtype selective nmda receptor antagonists
HUP0201937A3 (en) Substituted 1,5-dihydropyrrol-2-on derivatives, process for producing them and pharmaceutical compositions containing them having nmda receptor antagonist effect
PL353613A1 (en) Application of oestrogen agonist/antagonist in production of a drug
HUP0300599A3 (en) Il-8 receptor antagonists, pharmaceutical compositions containing them and their use
PL360885A1 (en) 10-aryl-11h-benzo [b]fluorene derivatives and analogs for medicinal use
HUP0302003A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
HK1076277A1 (en) Novel vitronectin receptor antagonist derivatives, method for preparing same, use thereof as medicines and pharmaceutical compositions containing
IL144299A0 (en) N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists
HUP0302614A3 (en) Il-8 receptor antagonists and pharmaceutical compositions containing them
GB0011817D0 (en) Antagonists of integrin receptors
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
HUP0300694A3 (en) Indole derivatives as mcp-1 receptor antagonists, their use, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees